A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Hairfollicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
Exploring the idea of transplanting miniaturized hairfollicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.
Hair loss therapies focusing on hairfollicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
PP405 is anticipated as a future treatment for dormant hairfollicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
The conversation discusses various factors affecting hair loss, not just DHT, and mentions treatments like Minoxidil, finasteride, and melatonin. Some users report personal experiences with these treatments and hormone tests, while others speculate on the role of hormones like prolactin and cortisol in hair loss.
This conversation discusses the advancements in treatments for hair loss, including finasteride, dutasteride, minoxidil and new promising treatments such as pyrilutamide and verteporfin. Other treatments discussed were taking minoxidil orally, tretinoin to turn non-responders into responders and microneedling to further boost growth.
Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.
User experienced hair loss from Norwood 3.5 to Norwood 5 with diffuse thinning after using a hair system for 2 years. Tried Redensyl, Capixyl, Bicapil, Biotin, multivitamins, Fin, and Min without significant improvement, seeking advice for hair recovery.
Carnosic acid in rosemary extract may enhance skin repair and promote hairfollicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.
Vitamin D may counteract DHT and help with hair growth, as seen in mice and humanhair cultures. Some users discuss using Vitamin D, magnesium, and other supplements for hair health, while others humorously note the success in mice.
A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
A new technique developed by scientists in Japan to reverse balding using hairfollicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.
Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hairfollicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.
Corticosterone inhibits GAS6, affecting hairfollicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
Hair loss treatments like finasteride, minoxidil, and hair transplants have side effects and limitations. There is hope for future advancements in stem cell therapy and hairfollicle regeneration, though skepticism about their effectiveness and timeline persists.
Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with humanfollicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
PP405 is a promising molecule that may reactivate dormant hairfollicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Yokohama University and Dr. Fukuda plan humanhair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.
Exercise, especially leg workouts, combined with finasteride and minoxidil, may enhance hair regrowth. Cold exposure, like cold showers, might further boost results.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hairfollicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.